NCT05654298View on ClinicalTrials.gov

Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin

NACompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

March 15, 2023

Study Completion Date

March 15, 2023

Conditions

Migraine

Interventions

DRUG

Sumatriptan

Sumatriptan 100 mg

DRUG

Ubrogepant

Ubrogepant 100 mg

Trial Locations (1)

3000

Center for Clinical Pharmacology, Leuven

All Listed Sponsors

lead

Universitaire Ziekenhuizen KU Leuven

OTHER